RBC Capital analyst Randall Stanicky said his “back and forth with management” at Akorn confirmed that the company received FDA approval for its generic version of Voltaren Gel, which the analyst notes represents the third ANDA approval from the company’s Amityville facility since October. Stanicky, who continues to watch the company’s ongoing litigation as well as its progress on the remediation of its Decatur and Somerset facilities, keeps a Sector Perform rating on Akorn shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.